- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02260193
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
June 7, 2022 updated by: Akebia Therapeutics
Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
94
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
El Granada, California, United States
-
Long Beach, California, United States
-
San Dimas, California, United States
-
Santa Clarita, California, United States
-
Whittier, California, United States
-
-
Colorado
-
Arvada, Colorado, United States
-
Westminster, Colorado, United States
-
-
Florida
-
Naples, Florida, United States
-
North Miami Beach, Florida, United States
-
-
Georgia
-
Augusta, Georgia, United States
-
-
New York
-
Astoria, New York, United States
-
-
Texas
-
Arlington, Texas, United States
-
Grand Prairie, Texas, United States
-
Greenville, Texas, United States
-
Houston, Texas, United States
-
-
Virginia
-
Mechanicsville, Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 79 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- 18 to 79 years inclusive
- Chronic Kidney Disease (CKD) Stage 5 on chronic hemodialysis for at least 3 months
- Anemia secondary to CKD treated with erythropoiesis stimulating agent and intravenous iron
Key Exclusion Criteria:
- Body mass index >44.0 kilograms per meter squared (kg/m^2)
- Transfusion within 8 weeks prior to Screening
- Alanine transaminase or total bilirubin >1.25x ULN
- Uncontrolled hypertension
- Class III or IV congestive heart failure
- Myocardial infarction, acute coronary syndrome, stroke or transient ischemic attack within 6 months prior to Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AKB-6548, starting dose 1
|
Starting dose 1. Oral dose administered once daily for 16 weeks.
Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 2. Oral dose administered once daily for 16 weeks.
Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 3. Oral dose administered three times weekly for 16 weeks.
Dose adjustment based on hemoglobin levels as defined in the protocol.
|
Experimental: AKB-6548, starting dose 2
|
Starting dose 1. Oral dose administered once daily for 16 weeks.
Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 2. Oral dose administered once daily for 16 weeks.
Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 3. Oral dose administered three times weekly for 16 weeks.
Dose adjustment based on hemoglobin levels as defined in the protocol.
|
Experimental: AKB-6548, starting dose 3
|
Starting dose 1. Oral dose administered once daily for 16 weeks.
Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 2. Oral dose administered once daily for 16 weeks.
Dose adjustment based on hemoglobin level as defined in the protocol.
Starting dose 3. Oral dose administered three times weekly for 16 weeks.
Dose adjustment based on hemoglobin levels as defined in the protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Pre-dose Average in Hemoglobin (Hgb) Level to The Mid-study Average
Time Frame: Pre-dose (Screening, Second Screening, and Baseline), Week 7, and Week 8
|
Change from pre-dose average was calculated by the mid-study average minus the pre-dose average.
The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits.
|
Pre-dose (Screening, Second Screening, and Baseline), Week 7, and Week 8
|
Change From Pre-dose Average in Hgb Level to The End-of-study Average
Time Frame: Pre-dose, Week 15, and Week 16
|
Change from pre-dose average was calculated by the end-of-study average minus the pre-dose average.
The pre-dose average was defined as the average of the 3 Hgb values that were obtained before dosing at the first screening visit, the second screening visit, and the Baseline visit; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.
|
Pre-dose, Week 15, and Week 16
|
Change From Mid-study Average in Hgb Level to The End-of-study Average
Time Frame: Week 7, Week 8, Week 15, and Week 16
|
Change from mid-study average was calculated by the end-of-study average minus the mid-study average.
The mid-study average was defined as the average of the 2 Hgb values that were obtained at the Week 7 and Week 8 visits; the end-of-study average was defined as the average of the 2 Hgb values that were obtained at the Week 15 and Week 16 visits.
|
Week 7, Week 8, Week 15, and Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Hgb
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline Hgb was defined as the average of the three samples obtained prior to dosing.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Hematocrit
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline Hematocrit was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Red Blood Cell (RBC) Count
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline RBC Count was defined as the average of the three samples obtained prior to dosing.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Absolute Reticulocyte Count
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline absolute reticulocyte count was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Percent Reticulocyte Count
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100.
Baseline percent reticulocyte count was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Reticulocyte Hgb Content
Time Frame: Baseline, Week 2, Week 4, Week 8, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline reticulocyte Hgb content was defined as the average of the three samples obtained prior to dosing.
|
Baseline, Week 2, Week 4, Week 8, and Week 16
|
Change From Baseline in Ferritin
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline ferritin was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Hepcidin
Time Frame: Baseline, Week 8, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline hepcidin was defined as the last observation before the first dose of study medication.
|
Baseline, Week 8, and Week 16
|
Change From Baseline in Total Iron-Binding Capacity (TIBC)
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline TIBC was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Transferrin Saturation (TSAT)
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as (visit value minus the Baseline value)/ Baseline value x 100.
Baseline TSAT was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change From Baseline in Iron
Time Frame: Baseline, Week 4, Week 8, Week 12, and Week 16
|
Change from Baseline was calculated as the visit value minus the Baseline value.
Baseline iron was defined as the last observation before the first dose of study medication.
|
Baseline, Week 4, Week 8, Week 12, and Week 16
|
Number of Participants Who Received Erythropoiesis-stimulating Agent (ESA) Rescue Therapy
Time Frame: Up to Week 16
|
ESA rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.
|
Up to Week 16
|
Number of Participants Who Received Blood Transfusion Rescue Therapy
Time Frame: Up to Week 16
|
Blood transfusion rescue therapy was administered in participants with Hgb ≤12.5 g/dL, and was stopped when Hgb reached ≥13.0 g/dL.
|
Up to Week 16
|
Mean Plasma Concentrations of Vadadustat
Time Frame: Pre-dialysis and post-dialysis on Week 2 and Week 16
|
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
|
Pre-dialysis and post-dialysis on Week 2 and Week 16
|
Mean Plasma Concentrations of Vadadustat-O-Glucuronide Metabolite
Time Frame: Pre-dialysis and post-dialysis on Week 2 and Week 16
|
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
|
Pre-dialysis and post-dialysis on Week 2 and Week 16
|
Mean Plasma Concentrations of Vadadustat-Acyl-Glucuronide Metabolite
Time Frame: Pre-dialysis and post-dialysis on Week 2 and Week 16
|
Blood samples for determination of plasma levels of Vadadustat were drawn just before and 10 minutes after completion of the dialysis session.
|
Pre-dialysis and post-dialysis on Week 2 and Week 16
|
Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to Week 20
|
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period.
A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period.
A SAE included AEs that met one or more of the following criteria/outcomes: death, lifethreatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.
|
Up to Week 20
|
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs
Time Frame: Up to Week 20
|
Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature.
The investigator was responsible for reviewing laboratory results for clinically significant changes.
|
Up to Week 20
|
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Time Frame: Up to Week 20
|
Parameters assessed for laboratory values included hematology, serum chemistry, urinalysis, iron indices, C-reactive protein, lipid profile, biomarkers, and pregnancy tests.
The investigator was responsible for reviewing laboratory results for clinically significant changes.
|
Up to Week 20
|
Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings
Time Frame: Up to Week 20
|
A standard 12-lead ECG was performed following dosing in a supine position for approximately 5 minutes.
ECGs were taken prior to vital sign assessments, circulatory access cannulation, and blood draws when possible.
Clinical significance was determined by the investigator.
|
Up to Week 20
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Intravenous Iron Replacement Therapy
Time Frame: Baseline, Week 8, and Week 16
|
Intravenous iron was administered throughout the study to maintain ferritin levels in the range of ≥100 ng/mL to ≤1200 ng/mL.
|
Baseline, Week 8, and Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 10, 2014
Primary Completion (Actual)
July 22, 2015
Study Completion (Actual)
July 22, 2015
Study Registration Dates
First Submitted
September 25, 2014
First Submitted That Met QC Criteria
October 6, 2014
First Posted (Estimate)
October 9, 2014
Study Record Updates
Last Update Posted (Actual)
July 1, 2022
Last Update Submitted That Met QC Criteria
June 7, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AKB-6548-CI-0011
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on AKB-6548
-
Mitsubishi Tanabe Pharma CorporationCompletedAnemia; Hemodialysis Dependent Chronic Kidney DiseaseJapan
-
Mitsubishi Tanabe Pharma CorporationCompletedAnemia; Peritoneal Dialysis Dependent Chronic Kidney DiseaseJapan
-
Akebia TherapeuticsSuspendedAnemia of Chronic Kidney DiseaseUnited States
-
Akebia TherapeuticsCompletedChronic Kidney DiseaseUnited States
-
Akebia TherapeuticsCompletedHepatic ImpairmentUnited States
-
Akebia TherapeuticsCompleted
-
The University of Texas Health Science Center,...United States Department of Defense; Akebia Therapeutics Inc.CompletedCoronavirus Infection | Acute Respiratory Distress SyndromeUnited States
-
Akebia TherapeuticsCompletedAnemia | Dialysis Dependent Chronic Kidney DiseaseJapan
-
Akebia TherapeuticsSuspendedAnemia of Chronic Kidney DiseaseUnited States
-
Akebia TherapeuticsCompletedAnemia | Non-dialysis Dependent Chronic Kidney DiseaseJapan